Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa.

Fazeli PK, Wang IS, Miller KK, Herzog DB, Misra M, Lee H, Finkelstein JS, Bouxsein ML, Klibanski A

The Journal of clinical endocrinology and metabolism23 Jan 2014Cited by 79 (Europe PMC)

PMID24456286PMCIDPMC3973785DOI10.1210/jc.2013-4105PepBankPUB-24456286

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with anorexia nervosa, posteroanterior spine BMD increased 6.0% with teriparatide versus 0.2% with placebo.
In plain wordsIn women with anorexia nervosa, teriparatide increased posteroanterior spine bone density more than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePosteroanterior spine BMD
Study
n = 21
Comparator
Placebo
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Posteroanterior spine BMD change
6%
teriparatide group
Posteroanterior spine BMD change
0.2%
placebo group
Source sentences
Summary
At 6 months, spine BMD increased significantly more with TPT (posteroanterior spine, 6.0% ± 1.4%; lateral spine, 10.5% ± 2.5%) compared with placebo (posteroanterior spine, 0.2% ± 0.7%, P < .01; lateral spine, -0.6% ± 1.0%; P < .01).
3 context sentences(design, population, supporting numbers)
Summary · context
The results remained significant after controlling for baseline body mass index, P1NP, and IGF-1.
Summary · context
This randomized, placebo-controlled trial at a clinical research center included 21 women with AN: 10 (mean age ± SEM, 47 ± 2.7 years) treated with TPT and 11 (47.1 ± 2.3 years) treated with placebo.
Summary · context
TPT (20 μg s.c.) or placebo was administered for 6 months.
Report a problemFND-2445628601
02HumanRandomized controlled trialEfficacy outcome
In women with anorexia nervosa, lateral spine BMD increased 10.5% with teriparatide versus -0.6% with placebo.
In plain wordsIn women with anorexia nervosa, teriparatide increased lateral spine bone density more than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLateral spine BMD
Study
n = 21
Comparator
Placebo
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Lateral spine BMD change
10.5%
teriparatide group
Lateral spine BMD change
−0.6%
placebo group
Source sentences
Summary
At 6 months, spine BMD increased significantly more with TPT (posteroanterior spine, 6.0% ± 1.4%; lateral spine, 10.5% ± 2.5%) compared with placebo (posteroanterior spine, 0.2% ± 0.7%, P < .01; lateral spine, -0.6% ± 1.0%; P < .01).
3 context sentences(design, population, supporting numbers)
Summary · context
The results remained significant after controlling for baseline body mass index, P1NP, and IGF-1.
Summary · context
This randomized, placebo-controlled trial at a clinical research center included 21 women with AN: 10 (mean age ± SEM, 47 ± 2.7 years) treated with TPT and 11 (47.1 ± 2.3 years) treated with placebo.
Summary · context
TPT (20 μg s.c.) or placebo was administered for 6 months.
Report a problemFND-2445628602
03HumanRandomized controlled trialEfficacy outcome
In women with anorexia nervosa, femoral neck BMD changes were comparable with teriparatide and placebo.
In plain wordsIn women with anorexia nervosa, femoral neck bone density changed similarly with teriparatide and placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD
Study
n = 21
Comparator
Placebo
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Changes in femoral neck (P = .4) and total hip (P = 0.8) BMD were comparable in both groups, as were changes in weight.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, placebo-controlled trial at a clinical research center included 21 women with AN: 10 (mean age ± SEM, 47 ± 2.7 years) treated with TPT and 11 (47.1 ± 2.3 years) treated with placebo.
Summary · context
TPT (20 μg s.c.) or placebo was administered for 6 months.
Report a problemFND-2445628603
04HumanRandomized controlled trialEfficacy outcome
In women with anorexia nervosa, total hip BMD changes were comparable with teriparatide and placebo.
In plain wordsIn women with anorexia nervosa, total hip bone density changed similarly with teriparatide and placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal hip BMD
Study
n = 21
Comparator
Placebo
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Changes in femoral neck (P = .4) and total hip (P = 0.8) BMD were comparable in both groups, as were changes in weight.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, placebo-controlled trial at a clinical research center included 21 women with AN: 10 (mean age ± SEM, 47 ± 2.7 years) treated with TPT and 11 (47.1 ± 2.3 years) treated with placebo.
Summary · context
TPT (20 μg s.c.) or placebo was administered for 6 months.
Report a problemFND-2445628604
05HumanRandomized controlled trialEfficacy outcome
In women with anorexia nervosa, teriparatide increased P1NP at 3 months, sustained at 6 months, versus unchanged levels with placebo.
In plain wordsIn women with anorexia nervosa, a bone formation marker increased with teriparatide but remained unchanged with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum P1NP
Study
n = 21
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Serum P1NP levels increased after 3 months of TPT treatment and remained at this higher level at 6 months, whereas P1NP levels were unchanged in the placebo group (P = .02).
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, placebo-controlled trial at a clinical research center included 21 women with AN: 10 (mean age ± SEM, 47 ± 2.7 years) treated with TPT and 11 (47.1 ± 2.3 years) treated with placebo.
Summary · context
TPT (20 μg s.c.) or placebo was administered for 6 months.
Report a problemFND-2445628606
06HumanRandomized controlled trialEfficacy outcome
In women with anorexia nervosa, weight changes were comparable with teriparatide and placebo.
In plain wordsIn women with anorexia nervosa, weight changed similarly with teriparatide and placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeWeight
Study
n = 21
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
20 μg · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Changes in femoral neck (P = .4) and total hip (P = 0.8) BMD were comparable in both groups, as were changes in weight.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, placebo-controlled trial at a clinical research center included 21 women with AN: 10 (mean age ± SEM, 47 ± 2.7 years) treated with TPT and 11 (47.1 ± 2.3 years) treated with placebo.
Summary · context
TPT (20 μg s.c.) or placebo was administered for 6 months.
Report a problemFND-2445628605
07HumanRandomized controlled trialSafety outcome
In women with anorexia nervosa, all teriparatide-treated subjects tolerated treatment well.
In plain wordsAll women with anorexia nervosa who received teriparatide tolerated it well.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableTolerability
Study
n = 10
Outcome group
Adverse events · Whole body
Studied dose
20 μg · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
TPT was well-tolerated by all subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, placebo-controlled trial at a clinical research center included 21 women with AN: 10 (mean age ± SEM, 47 ± 2.7 years) treated with TPT and 11 (47.1 ± 2.3 years) treated with placebo.
Summary · context
TPT (20 μg s.c.) or placebo was administered for 6 months.
Report a problemFND-2445628607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.